Keywords
Sintilimab
Lenvatinib
Interventional therapy
Submitted : 2025-04-29
Accepted : 2025-05-14
Published : 2025-05-29
Abstract
Objective: To observe the control effect of interventional therapy combined with lenvatinib and sintilimab in patients with intermediate and advanced liver cancer. Methods: 82 patients with intermediate and advanced liver cancer who visited from January 2022 to January 2025 were selected as samples and randomly divided into two groups. Group A received interventional therapy combined with lenvatinib and sintilimab, while Group B received interventional therapy combined with lenvatinib. Disease remission rate, adverse reactions, liver function indicators, and tumor marker indicators were compared between the two groups. Results: The disease control rate (DCR) in Group A was higher than that in Group B (P < 0.05). There was no difference in adverse reaction rates between Group A and Group B (P > 0.05). Total bilirubin (TBil), aspartate aminotransferase (AST), and alanine aminotransferase (ALT) levels in Group A were lower than those in Group B (P < 0.05). Carcinoembryonic antigen (CEA), alpha-fetoprotein (AFP), and alpha-L-fucosidase (AFU) levels in Group A were also lower than those in Group B (P < 0.05). Conclusion: Intermediate and advanced liver cancer patients receiving interventional therapy combined with lenvatinib and sintilimab showed reduced tumor marker levels, lessened liver function damage, and a high disease control rate and treatment safety.
References
Hui F, Ma S, Pei X, 2024, Clinical Application of Sintilimab and Bevacizumab Combined with Transarterial Chemoembolization in Patients with Intermediate and Advanced Stage Liver Cancer. Chinese Journal of Modern Medicine, 34(6): 86–91.
Expert Committee for the Compilation of “Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2024 Edition),” Zhou Jian, 2024, Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2024 Edition). Chinese Journal of Clinical Medicine, 31(2): 277–334.
Peng Y, Li H, Yang W, et al., 2023, Study on the Clinical Efficacy of PD-1 Inhibitors Combined with Lenvatinib in the Treatment of Elderly Patients with Intermediate and Advanced Stage Primary Liver Cancer. Journal of Practical Hepatology, 26(1): 112–115.
Dong Y, Niu M, Luo Y, et al., 2024, Clinical Study of Sintilimab Combined with Targeted Therapy in the Treatment of Intermediate and Advanced Stage Primary Liver Cancer. Liver, 29(9): 1068–1073.
Ding X, Sun W, Shen Y, et al., 2022, Efficacy and Safety of Lenvatinib Combined with Sintilimab as Second-line Treatment for Intrahepatic Cholangiocarcinoma. Journal of Clinical Hepatology, 38(8): 1813–1818.
Li W, Tang J, Yi C, et al., 2024, A Case of Successful Conversion of Giant Hepatocellular Carcinoma with Sintilimab, Lenvatinib, and TACE. Journal of Hepatopancreatobiliary Surgery, 36(5): 294–296 + 301.
Teng Y, Ding X, Li W, et al., 2021, Efficacy and Adverse Reactions of Programmed Cell Death Receptor 1 Inhibitors Combined with Lenvatinib in the Treatment of Advanced Primary Liver Cancer. Journal of Clinical Hepatology, 37(3): 606–610.
Zhang X, Peng S, 2024, Clinical Efficacy of Different Interventional Regimens Combined with Sintilimab and Lenvatinib in the Treatment of Intermediate and Advanced Stage Liver Cancer. International Journal of Surgery, 51(4): 253–259.
Li H, Liao B, Wang B, 2025, Application Effect of Lenvatinib and Tislelizumab Combined with Interventional Therapy in Patients with Intermediate and Advanced Stage Liver Cancer. Oncology Progress, 23(4): 476–479.
Yang S, Jiang C, Jian W, et al., 2024, Effect Analysis of Hepatic Arterial Infusion Chemotherapy Combined with Sintilimab and Bevacizumab in the Treatment of Intermediate and Advanced Stage Hepatocellular Carcinoma After Failure of Lenvatinib. Chongqing Medicine, 53(21): 3257–3263.